Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
MSC On Other Exchanges
All times are local (Market data is delayed by at least 15 minutes).

meridex software corp (MSC) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MERIDEX SOFTWARE CORP (MSC)

Related News

No related news articles were found.

meridex software corp (MSC) Related Businessweek News

No Related Businessweek News Found

meridex software corp (MSC) Details

InMed Pharmaceuticals Inc., a biopharmaceutical company, engages in the development of cannabis-based botanical and non-botanical therapies. Its Drug Discovery and Development division utilizes its proprietary Cannabinoid Drug Design Platform to identify new bioactive compounds within the marijuana plant that interact with various gene responsible for specific diseases. The company’s Cultivation and Breeding division researches and develops individual strains and clones for producing the raw material bases for future pharmaceutical research. It focuses on various therapeutic areas, including glaucoma, inflammation/pain/arthritis, Huntington's and Epilepsy diseases, diabetes, obesity, cancer, and angiogenesis. InMed Pharmaceuticals Inc. has strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. is based in Vancouver, Canada.

meridex software corp (MSC) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: C$45.0K
Chief Financial officer
Total Annual Compensation: C$14.6K
Compensation as of Fiscal Year 2014.

meridex software corp (MSC) Key Developments

InMed Pharmaceuticals Inc. Appoints Paul Brennan as Board of Director

InMed Pharmaceuticals Inc. announced the appointment of Paul Brennan to the company's Board of Directors. Mr. Brennan brings more than 25 years of experience in building, leading and advising top-performing pharmaceutical and biotechnology companies in Europe, Canada and the United States. Mr. Brennan is currently Senior Vice-President of Business Development at Arbutus Biopharma (formerly Tekmira Pharmaceuticals). Mr. Brennan served as CEO of Altair Therapeutics. Prior to Altair, Mr. Brennan was Senior Vice President, Business Development at Aspreva Pharmaceuticals.

InMed Pharmaceuticals Inc. Announces Completion and Validation of Preclinical Pain Modelling

InMed Pharmaceuticals Inc. announced the completion and validation of preclinical pain modeling. Following the recently completed in silico work using InMed's proprietary "IDP" platform to identify cannabinoid compounds for its orofacial pain program, InMed completed validation of the preclinical pain model using nerve growth factor (NGF) induced pain in rats. Preliminary data indicates that primary afferent neurons innervating the masseter muscles of female rats expressed CB1 and CB2 and these expressions were found in satellite glial cells in the trigeminal ganglion. InMed is currently conducting further preclinical works using selected cannabinoid compound compounds to develop a new therapy for orofacial pain.

InMed Pharmaceuticals Inc. Announces Positive In-Vitro Study Results

InMed Pharmaceuticals Inc. announced that it has obtained positive response from its pre-clinical research on INM-750 tested in various in vitro assays. The INM-750 is a proprietary phytocannabinoid based compound for the treatment of epidermolysis bullosa simplex (EBS), a rare genetically inherited skin disorder. INM-750 is designed to modulate skin growth, differentiation and inflammation that are signature characteristics of EBS. The company anticipates commencing human proof of concept clinical studies of INM-750 in February, 2016 with initial data expected by third quarter of 2016 after which the company will seek orphan drug designation for INM-750 with the US Food and Drug Administration (FDA).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MSC:CN C$0.00 CAD 0.00

MSC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MSC.
View Industry Companies

Industry Analysis


Industry Average

Valuation MSC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERIDEX SOFTWARE CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at